Fierce Pharma Mix Logo.png Fierce Pharma Mix Logo.png
Webinar

The Next Wave of AI: the Impact of LQMs on the Pharmaceutical Industry

Available on-demand
60 Minutes
Join Fierce and SandboxAQ as we explore cutting-edge technology that is pioneering the next wave of AI.
 
As the pharmaceutical landscape evolves, the need for innovative solutions to traditional challenges becomes paramount. This session will explain how Large Quantitative Models (LQMs) are redefining the drug discovery process, enabling researchers to navigate the complexity of the chemical space with unprecedented speed and accuracy.
 
This webinar is a can’t-miss opportunity for professionals who are eager to learn about the future of drug discovery and the role of AI in shaping it. Register today.
 
Webinar Takeaways
 
  1. Introduction to LQMs: Learn about Large Quantitative Models and their role in simulating intricate biological behaviors. Discover how these models are complementary and maximize the impact of expensive, time-intensive physical experiments, significantly accelerating the discovery timeline.
  2. Understanding the challenge of the traditional drug discovery framework and the blockers that slow down innovation.
  3. We will discuss the types of data that power LQMs, including molecular simulations, rigorous physics-based methods, foundational methods, and their integration into generative AI solutions.
  4. Learn how LQM technologies can enhance protein target identification, rational drug design, structure-based methods, pharmacokinetics, and pharmacodynamics properties faster than traditional methodologies, streamlining the clinical candidate identification process.
  5. Explore how AI analyzes biological data using LQM powered by effective knowledge graph solutions, to identify potential drug targets and predict compound activity, thus reducing screening costs and optimizing lead compounds through advanced structure-activity relationship modeling. A compelling case study will illustrate these advancements in practice.
  6. Applications of LQM in drug development, knowledge graph-based LQM and patient selection in clinical trial development. Address critical considerations surrounding data privacy, ethical implications, and regulatory compliance, highlighting the necessity of integrating AI with existing workflows. 

Speakers

Joesph-HS.png

Dr. Joseph Lehár

Dr. Joseph Lehár brings over 20 years experience using data and digital technologies towards transforming health care. He advises biotechs, incubators, and venture funds, including Paris-based Owkin, where he recently joined their SAB after three years as SVP R&D Strategy - building and executing Owkin’s transformation towards AI-driven precision medicine. Previously, Joseph led cross-functional data science teams and drove scientific projects at J&J/Janssen, Google/Verily, Novartis, and CombinatoRx. His first career in astrophysics focused on gravitational lensing at Harvard, Cambridge Univ, and MIT. For more information, see Joseph’s LinkedIn and gScholar profiles.

Andrea-HS.png

Andrea Bortolato

Andrea Bortolato is the Vice President of Drug Discovery at SandboxAQ, bringing over 20 years of experience in computational chemistry and drug discovery. Throughout his career, he has worked in biotechnology, pharmaceuticals, and agrochemistry, holding more than 50 scientific patents and publications, including three in Nature. Prior to joining SandboxAQ, Andrea successfully led drug discovery project teams at Bristol-Myers Squibb (BMS), Schrodinger, Heptares (now Nxera Pharma), and Syngenta. He has experience working on both internal projects and collaborations with companies such as Takeda, AstraZeneca, Cubist, Morphic, and Structure Therapeutics. Andrea holds a PhD in computational chemistry, earned in partnership between the University of Padua in Italy and the University of Geneva in Switzerland. He then completed a postdoctoral fellowship at Mount Sinai School of Medicine in New York City.

Register here to watch on-demand!

Duration:
60 Minutes